Il-17a binding proteins

A binding molecule that is capable of binding human IL-17A comprising a heavy chain variable immunoglobulin (VH) domain selected from the group consisting of (a), (b), (c), (d), and (e):

• (a) a CDR1 comprising an amino acid sequence selected from SEQ ID NOs:
• 1, 5, 9, 13, 17, 21, 25, 29, 33, 37, 41, 49, 57, 65, 69, 77, 93, 97, 101, 113, 117, 121, 125, 129, 141, 145, 149, 157, 165, 173, 177, 181, 193, 197, 205, 213, 217, 221, 225, 233, 237, 245, 442, 446, 450, 454, 458, and 462;
• a CDR2 comprising an amino acid sequence selected from SEQ ID NOs:
• 2, 6, 10, 14, 18, 22, 26, 30, 34, 38, 42, 50, 58, 66, 70, 78, 94, 98, 102, 114, 118, 122, 126, 130, 142, 146, 150, 158, 166, 174, 178, 182, 194, 198, 206, 214, 218, 222, 226, 234, 238, 246, 443, 447, 451, 455, 459, and 463;
• and a CDR3 comprising an amino acid sequence selected from SEQ ID NOs:
• 3, 7, 11, 15, 19, 23, 27, 31, 35, 39, 43, 51, 59, 67, 71, 79, 95, 99, 103, 115, 119, 123, 127, 131, 143, 147, 151, 159, 167, 175, 179, 183, 195, 199, 207, 215, 219, 223, 227, 235, 239, 247, 444, 448, 452, 456, 460, and 464;
• or
• (b) a CDR1 comprising an amino acid sequence selected from SEQ ID NOs:
• 249, 253, 257, 261, 265, and 273;
• a CDR2 comprising an amino acid sequence selected from SEQ ID NOs:
• 250, 254, 258, 262, 266 and 274, and a CDR3 sequence comprising an amino acid sequence selected from SEQ ID NOs:
• 251, 255, 259, 263, 267, and 275;
• or
• (c) a CDR1 comprising an amino acid sequence selected from SEQ ID NOs:
• 285, 289, 293, 297, 301, 305, 317, 321, 325, 329, 333, and 337;
• a CDR2 comprising an amino acid sequence selected from SEQ ID NOs:
• 286, 290, 294, 298, 302, 306, 318, 322, 326, 330, 334 and 338, and a CDR3 sequence comprising an amino acid sequence selected from SEQ ID NOs:
• 287, 291, 295, 299, 303, 307, 319, 323, 327, 331, 335 and 339;
• or
• (d) a CDR1 sequence comprising SEQ ID NO:
• 341, a CDR2 sequence comprising SEQ ID NO:
• 342, and a CDR3 sequence comprising SEQ ID NO:
• 343 or
• (e) a CDR1 sequence comprising SEQ ID NO:
• 345, a CDR2 sequence comprising SEQ ID NO:
• 346, and a CDR3 sequence comprising SEQ ID NO:
• 347.

A binding molecule, comprising:

• a heavy chain variable immunoglobulin (VH) domain that comprises a CDR1, a CDR2, and a CDR3 sequence, wherein said CDR1 sequence comprises the amino acid sequence of SEQ ID NO:
• 5;
• wherein said CDR2 sequence comprises the amino acid sequence of SEQ ID NO:
• 6;
• and wherein said CDR3 sequence comprises the amino acid sequence of SEQ ID NO:
• 7.

A pharmaceutical composition, comprising:

• a pharmaceutical carrier;
• and
• a binding molecule that binds human IL-17A, said binding molecule comprising a heavy chain variable immunoglobulin (VH) domain that comprises a CDR1, a CDR2, and a CDR3 sequence, wherein said CDR1 sequence comprises the amino acid sequence of SEQ ID NO:
• 5;
• wherein said CDR2 sequence comprises the amino acid sequence of SEQ ID NO:
• 6;
• and wherein said CDR3 sequence comprises the amino acid sequence of SEQ ID NO:
• 7.